Therapeutic Benefit of Upadacitinib in Severe Post-Proctectomy (Class 4) Perianal Crohn's Disease: A Three-Patient Case Series.

IF 4.3 3区医学 Q1 GASTROENTEROLOGY & HEPATOLOGY

Inflammatory Bowel Diseases Pub Date : 2025-09-24 DOI:10.1093/ibd/izaf216

Luke Nathan Hanna, Baseer Quraishi, Theo Pelly, Phillip Lung, Phil Tozer, Ailsa Hart, Serre-Yu Wong, Nick Powell

引用次数: 0

Abstract

This case series describes striking clinical and radiological responses in 3 Crohn's disease patients with persistent perineal complications following proctectomy treated with upadacitinib. It highlights the potential of advanced therapies for this refractory inflammatory bowel disease phenotype with limited treatment options.

查看原文本刊更多论文

Upadacitinib治疗重度（4级）肛周克罗恩病的疗效：一个3例病例系列

本病例系列描述了3例克罗恩病患者在接受upadacitinib治疗后出现持续会阴并发症的显著临床和放射学反应。它强调了这种治疗选择有限的难治性炎症性肠病表型的先进疗法的潜力。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Inflammatory Bowel Diseases 医学-胃肠肝病学

CiteScore

9.70

自引率

6.10%

发文量

462

审稿时长

1 months

期刊介绍： Inflammatory Bowel Diseases® supports the mission of the Crohn''s & Colitis Foundation by bringing the most impactful and cutting edge clinical topics and research findings related to inflammatory bowel diseases to clinicians and researchers working in IBD and related fields. The Journal is committed to publishing on innovative topics that influence the future of clinical care, treatment, and research.